Pfizer (NYSE:PFE) Trading 1% Higher - Time to Buy?

Key Points

• Pfizer shares rose 1% to $27.04 in mid-day trading, with volume about 12% above the average session volume.
• Analysts remain cautious: Pfizer has an average rating of “Hold” and a consensus price target of $28.28, although one research firm recently upgraded the stock to “Buy.”
• Pfizer beat quarterly expectations with $0.77 in EPS and $15.03 billion in revenue, while maintaining a quarterly dividend of $0.43 per share, equivalent to a 6.4% annualized yield.

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price rose 1% during trading on Monday . The company traded as high as $27.19 and last traded at $27.04. Approximately 47,433,031 shares changed hands during mid-day trading, an increase of 12% from the average session volume of 42,529,801 shares. The stock had previously closed at $26.76.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. UBS Group reissued a "neutral" rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Wolfe Research reaffirmed an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Pfizer in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $28.28.

Pfizer Stock Up 1.0%

The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $154.12 billion, a PE ratio of 35.58 and a beta of 0.34. The firm's fifty day moving average is $25.02 and its 200-day moving average is $26.17.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company earned $0.78 EPS. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.97 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio is currently 226.32%.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the business. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Keb Asset Management LLC acquired a new position in Pfizer during the second quarter worth about $26,000. HFM Investment Advisors LLC increased its holdings in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 427 shares in the last quarter. Evolution Wealth Management Inc. lifted its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer during the 4th quarter valued at approximately $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source